Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-086571 · Präparat HOS-083306
6
When Tasmar was given together with levodopa/carbidopa and desipramine, there was no significant
change in blood pressure, pulse rate and plasma concentrations of desipramine. Overall, the frequency
of adverse reactions increased slightly. These adverse reactions were predictable based on the known
adverse reactions to each of the three drugs individually. Therefore, caution should be exercised when
potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered
to Parkinson’s disease patients being treated with Tasmar and levodopa preparations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) carbidopa (HOS-086562) desipramine (HOS-086249) venlafaxine (HOS-086573) levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage f0044f3a960b0b3d966c24892293ccebf08b5ee7404000f75c3cf3acef4c3a06 · Zeichen 2983–3578 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-086596 · Präparat HOS-083306
18
When Tasmar was given together with levodopa/carbidopa and desipramine, there was no significant
change in blood pressure, pulse rate and plasma concentrations of desipramine. Overall, the frequency
of adverse reactions increased slightly. These adverse reactions were predictable based on the known
adverse reactions to each of the three drugs individually. Therefore, caution should be exercised when
potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered
to Parkinson’s disease patients being treated with Tasmar and levodopa preparations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) carbidopa (HOS-086562) desipramine (HOS-086249) venlafaxine (HOS-086573) levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage b4c09358b64cd61c631b98ee7ba8a6fd06fdf4cab95eeb6c6db1a7ea0d8dd1d1 · Zeichen 2981–3577 im Abschnitt
Wechselwirkungen · Comtess
Comtess 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-087880 · Präparat HOS-083575
4
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) dopamine (HOS-085948) venlafaxine (HOS-086573) dobutamine (HOS-086565) apomorphine (HOS-086566) selegiline (HOS-086575) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-18T01:00:00Z · SHA-256 fa3d8879d7f9d8835c303451aba5afa0417c9a42bba423f3f71a40c3f8d94d33 · Passage 3c592197fa296402268e76a507959b26c502f61c3b5567c38fa7d68d94e5d6c3 · Zeichen 418–1090 im Abschnitt
Wechselwirkungen · Comtan
Comtan 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-087903 · Präparat HOS-083583
4
imipramine or between entacapone and moclobemide. Similarly, no interactions between entacapone
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) dopamine (HOS-085948) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573) rimiterol (HOS-087904) dobutamine (HOS-086565) apomorphine (HOS-086566) selegiline (HOS-086575) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T16:36:00Z · SHA-256 5a934525674e083ec4dd9056db2e81d6f6bd7e081e45463e4be2195fdd4c2470 · Passage 607c7c228205279947c9a575e4730f7853ea1c18929afcfc4a48e376ed14e9a1 · Zeichen 322–1089 im Abschnitt
Wechselwirkungen · Stalevo
Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Stalevo 100 mg/25 mg/200 mg film-coated tablets Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Stalevo 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-112313 · Präparat HOS-093651
Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the
concomitant use of tricyclic antidepressants and levodopa/carbidopa. Interactions between entacapone
and imipramine and between entacapone and moclobemide have been investigated in single dose
studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number
of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and
entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants,
noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal
products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No
pharmacodynamic interactions have been observed. However, caution should be exercised when these
medicinal products are used concomitantly with Stalevo (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-06T10:34:00Z · SHA-256 efa438d75f473f63d3f59b043f928d6ef3dd686a6813356b7fc3207963682e9f · Passage 8aaf8eda160f67f7912e0de14bb48e24fb25b023852e8cfb4dece046a9b95365 · Zeichen 1018–1973 im Abschnitt
Wechselwirkungen · Entacapone Teva
Entacapone Teva 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-213534 · Präparat HOS-155128
In single-dose studies in healthy volunteers, no interactions were observed between entacapone and
imipramine or between entacapone and moclobemide. Similarly, no interactions between entacapone
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline
and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-structured
compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-
methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when these
medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) dopamine (HOS-085948) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573) dobutamine (HOS-086565) apomorphine (HOS-086566) selegiline (HOS-086575) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-28T17:49:00Z · SHA-256 a1bd223632cc773f7d6b9c4c6c3717b6bb040156eb55488dc0e81428b647ce20 · Passage d28934dc54dbd13dea735cd13a3c66783dab1bfafac92610aa00a62b311d4345 · Zeichen 171–1035 im Abschnitt
Wechselwirkungen · Entacapone Orion
Entacapone Orion 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-215641 · Präparat HOS-155488
4
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) dopamine (HOS-085948) venlafaxine (HOS-086573) dobutamine (HOS-086565) apomorphine (HOS-086566) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-24T11:10:00Z · SHA-256 3eb4e83d0bea670f09b10f71bef77c228824c1e10efb8c36a0cf3aa5315b81fe · Passage dd1d6a1b67875866d02a2feca2ca369e0b23c9161352e02aadb463f889fe1ab8 · Zeichen 511–1090 im Abschnitt
Wechselwirkungen · Levodopa/Carbidopa/Entacapone Orion
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-125970 · Präparat HOS-096201
Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the
concomitant use of tricyclic antidepressants and levodopa/carbidopa. Interactions between entacapone
and imipramine and between entacapone and moclobemide have been investigated in single dose
studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number
of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and
entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants,
noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal
products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No
pharmacodynamic interactions have been observed. However, caution should be exercised when these
medicinal products are used concomitantly with Levodopa/Carbidopa/Entacapone Orion (see
sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T13:17:00Z · SHA-256 0b58e7c710f75a6903225e3110b4255e26a78fbf567494b5c767ec9955060634 · Passage 630570400fedc106e23f901cf20372986519c19c30e84dc7743bdaf96f4242cc · Zeichen 1074–2057 im Abschnitt
Gegenanzeigen · Mirvaso
Mirvaso 3 mg/g gel · Abschnitt 4.3 · PDF-Seite 3
HOS-127955 · Präparat HOS-096493
Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or
moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline,
mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) imipramine (HOS-085907) moclobemide (HOS-087879) selegiline (HOS-086575) mianserin (HOS-127959)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T13:53:00Z · SHA-256 9c7e643a7b3870885a0241d066a8ccdd78ce3d5940f001edca4fc861c64df7e0 · Passage 29d75b99b6a535d93fe83e46597f39dc50ba5108df6a37a0cff7d8fcfb41bd76 · Zeichen 126–392 im Abschnitt
Wechselwirkungen · Ongentys
Ongentys 25 mg hard capsules Ongentys 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-129707 · Präparat HOS-096787
There is limited experience with opicapone when used concomitantly with tricyclic antidepressants
and noradrenaline re-uptake inhibitors (e.g. venlafaxine, maprotiline and desipramine). Thus, their
concomitant use should be considered with appropriate caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) desipramine (HOS-086249) venlafaxine (HOS-086573)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-07T10:00:00Z · SHA-256 5440c5fa9668dadbdfe2b487d148f72232f8fdbfa654e4a6492429ca5c3f530f · Passage d961ff84f967c9db0a970d84a0c97099380d70c56fc76e4c2fbb44fb0ee9d462 · Zeichen 1375–1635 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.